Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BXQ-350 and Radiation in Newly Diagnosed DIPG and DMG
NCT04771897Phase 1Terminated
- Sponsor
- Bexion Pharmaceuticals
- Start
- May 2021
- Primary completion
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of BXQ-350 in diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG) (2 arms), sponsored by Bexion Pharmaceuticals. Primary endpoints: Incidence of Treatment Emergent Adverse Events at 12 months, Maximum Tolerated Dose at 12 months and 2 more. Started May 2021; status: terminated.
02
Drugs
BXQ-350
03
Conditions
diffuse intrinsic pontine glioma (DIPG)diffuse midline glioma (DMG)
Beyond the preview
Go deeper on NCT04771897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04771897.